학술논문
Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
Document Type
Article
Author
Source
Subject
*HEMATOPOIETIC stem cell transplantation
*HODGKIN'S disease
*SALVAGE therapy
*
*
Language
ISSN
1042-8194
Abstract
It is important to note that the BvB regimen was administered exclusively in the outpatient setting, and more interestingly, none of the patients from the BvB-group required admission/hospitalization during the treatment period. .05 Number of patients with bulky disease (>=10 cm) 1 1 0 Number of patients required hospitalization 30 30 0 Days of admission 10 (0-38) 13 (6-36) 0 Response in whole patients Complete 21 (45%) 11 (36%) 10 (62%) 0 Since a variety of conditioning regimens were used among the autografted patients and two patients (both from platinum-based group) received Bv as maintenance post ASCT, the overall effect of BvB vs. the platinum-based salvage regimens cannot be accurately assessed. Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and "bridge" to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma. [Extracted from the article]